anti-cd47

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Anti-CD47 Antibody (B6.H12) is a chimeric mouse IgG1 κ antibody that specifically targets human CD47. The recommended isotype control for Anti-CD47 Antibody (B6.H12) is Mouse IgG1 kappa, Isotype Control.

Anti-CD47 (A4) antibody is a kind of antibody that can be used for Blocking, functional assays, FC and other related research.

Anti-CD47 (h4C1) antibody is a kind of antibody that can be used for Block, ELISA, FC and other related research.

Anti-Mouse CD47/IAP Antibody (MIAP301) is an IgG2a, κ antibody inhibitor derived from rats that targets mouse CD47/IAP.

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ antibody inhibitor targeting CD47/IAP in mice, rats, and humans.

Anti-human/mouse CD47 (VxP037-01LC1) antibody is a kind of antibody that can be used for blocking and other related research.

CC-90002, a humanized anti-CD47 monoclonal antibody (mAb), demonstrates high affinity for CD47, characterized by a subnanomolar dissociation constant (K d). It is utilized in the research of hematologic malignancies and solid tumors [1] [2].

Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody that targets CD47 without inducing red blood cell hemagglutination. Ligufalimab enhances phagocytosis and demonstrates significant antitumor activity. Due to its safety and activity profile, Ligufalimab is considered a promising therapeutic antibody candidate in oncology research.

Lemzoparlimab (TJ011133) is a differentiated anti-CD47 humanized antibody with anti-tumor activity, used in the study of myeloid leukemia.

Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications.

STI-6643 is a fully human IgG4 antibody that targets and binds to CD47. It exhibits potent anti-tumor activity with negligible toxicity towards red blood cells and lymphocytes. The isotype control for STI-6643 can be referenced as HumanIgG4(S228P) kappa, Isotype Control.